Overview

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Status:
NOT_YET_RECRUITING
Trial end date:
2027-04-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).
Phase:
PHASE3
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated